For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
KPV (Lysine-Proline-Valine) is a tripeptide derived from the C-terminal region of alpha-melanocyte stimulating hormone (alpha-MSH). It captures the primary anti-inflammatory activity of the parent molecule while avoiding melanogenic and broader hormonal effects. KPV has been investigated in over 50 peer-reviewed publications spanning 20 or more years. Its most scientifically distinctive feature is PepT1-mediated oral uptake, selectively upregulated in inflamed colonic tissue in IBD, creating inherent disease-site targeting. No completed human clinical trials exist for any indication. FDA PCAC review scheduled July 2026 for compounding status determination.
KPV is currently classified as a research peptide with no FDA or EMA approval and no completed human clinical trials for any indication. All available dosing and safety information comes from preclinical animal studies, cell culture experiments, and limited anecdotal reports. Every use case in this profile must be read through the lens of preclinical-only evidence.
FDA regulatory update (April 2026): KPV was removed from Category 2 effective April 22, 2026, because the original nominator withdrew the nomination. This is a procedural change: removal from Category 2 does not place KPV on the 503A positive list and does not authorize compounding pharmacies to produce it. The FDA Pharmacy Compounding Advisory Committee is scheduled to review KPV on July 23-24, 2026 (Docket FDA-2025-N-6895) for possible inclusion on the 503A Bulks List. Until that review concludes and FDA acts on the committee's recommendation, the compounding status of KPV remains in transition. BPC-157 and TB-500 are on the same July 2026 PCAC docket.
WADA status: KPV is not listed on the 2026 WADA Prohibited List. It is not an alpha-MSH derivative covered under S2 (growth factors) and does not fall within any currently named prohibited class. Athletes subject to WADA testing may use KPV without risk of sanction as of 2026. This status is reviewed annually.
This distinguishes KPV from BPC-157 (WADA prohibited, FDA Category 2), TB-500 (WADA prohibited, FDA April 2026 procedural removal), and TB4 (WADA prohibited, FDA investigational). KPV is the least restrictively regulated compound among the free profiles in this series.
The patent landscape for KPV is limited by its naturally-derived status as a fragment of an endogenous hormone. This reduces commercial incentive for sponsored Phase 1/2 trials and is the primary structural barrier to clinical development, not scientific concern about the compound itself.
KPV (Lysine-Proline-Valine) is a tripeptide derived from the C-terminal region of alpha-melanocyte stimulating hormone (alpha-MSH), specifically representing amino acids 11 to 13 of the 13-amino acid parent peptide. Alpha-MSH is itself a cleavage product of proopiomelanocortin (POMC) and carries potent anti-inflammatory and immunomodulatory properties.
What makes KPV scientifically distinctive is a key pharmacological property: most of the anti-inflammatory activities of the full alpha-MSH molecule can be attributed to its C-terminal KPV tripeptide alone. This means KPV captures the primary therapeutic activity of the parent hormone while avoiding alpha-MSH's other effects, particularly melanogenesis and broader hormonal actions mediated through the full melanocortin receptor family. KPV delivers targeted anti-inflammatory and immunomodulatory action without the hormonal side-effect profile of its parent.
KPV has been investigated in over 50 peer-reviewed publications spanning more than two decades of research, exhibiting efficacy in multiple preclinical models of inflammatory bowel disease, dermatitis, wound healing, and infection. It demonstrates superior stability compared to the parent alpha-MSH peptide, with resistance to enzymatic degradation. Its small tripeptide size allows it to be transported across intestinal epithelium via PepT1 (di/tripeptide transporter), a property that is selectively upregulated in inflamed colonic tissue in IBD, creating a uniquely self-targeting oral delivery mechanism.
KPV's mechanism is unusual in that it operates predominantly intracellularly, entering cells and inhibiting inflammatory signaling pathways inside the nucleus, rather than acting on surface receptors like most anti-inflammatory compounds. This distinguishes it from corticosteroids, NSAIDs, and most biologics.
KPV operates through a mechanism that is fundamentally different from most anti-inflammatory compounds: it works intracellularly rather than at the cell surface. While NSAIDs inhibit extracellular enzymes and biologics like TNF inhibitors work at the cell membrane surface, KPV enters the cell and inhibits inflammatory signaling pathways inside the nucleus.
The primary targets are NF-kB (Nuclear Factor kappa B), the master transcription factor controlling inflammatory gene expression, and the NLRP3 inflammasome, the intracellular multiprotein complex responsible for cleaving IL-1beta. By inhibiting these two central nodes of the inflammatory cascade at nanomolar concentrations, KPV suppresses a broad spectrum of pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) while enhancing anti-inflammatory IL-10. A 2025 study (Sung et al., Tissue and Cell) confirmed that KPV additionally inhibits the ERK/p38 MAPK axis and caspase-1 activation in human keratinocytes, expanding the established NF-kB mechanism to include MAPK pathway suppression.
A distinctive feature is the PepT1 (di/tripeptide transporter 1) uptake mechanism. PepT1 is a transport protein normally expressed in the small intestine that is selectively upregulated in colonic epithelium during IBD inflammation. This creates an elegant self-targeting delivery mechanism: KPV given orally is preferentially transported into inflamed colonic cells, the cells that need it most, while having lower uptake in non-inflamed tissue. This property underpins KPV's most scientifically compelling application in IBD.
KPV also has direct antimicrobial activity against Staphylococcus aureus (including MRSA) and Candida albicans at physiological picomolar concentrations via cAMP elevation in the pathogen. Unlike immunosuppressive drugs, KPV does not impair neutrophil killing of bacteria: it enhances it. This dual anti-inflammatory and antimicrobial profile is the opposite of conventional immunosuppressive IBD therapies.
The Dalmasso et al. (2008) Gastroenterology paper provided the foundational mechanistic insight: nanomolar concentrations of KPV inhibit NF-kB and MAP kinase inflammatory signaling pathways and reduce pro-inflammatory cytokine secretion. Crucially, this effect is mediated through hPepT1 expressed in immune and intestinal epithelial cells, and PepT1 expression is upregulated in inflamed colonic tissue in IBD. The sicker the gut, the more efficiently it takes up KPV: an inherently disease-site-targeted oral delivery mechanism.
In DSS-colitis and TNBS-colitis murine models (the standard preclinical IBD surrogates), oral KPV reduced incidence and severity of colitis with significant decreases in pro-inflammatory cytokine expression. KPV-treated animals showed earlier recovery, significantly stronger body weight regain, and histologically reduced inflammatory infiltrates confirmed by significant reduction in MPO activity. In MC1Re/e mice with nonfunctional melanocortin-1 receptors, KPV treatment rescued all animals from death during DSS colitis, demonstrating effects at least partially independent of MC1R signaling.
The 2017 Xiao et al. Molecular Therapy paper advanced the delivery science substantially: hyaluronic acid-functionalized nanoparticles (approximately 272.3 nm particle size) loaded with KPV mediated targeted delivery to colonic epithelial cells and macrophages and produced combined effects against ulcerative colitis by both accelerating mucosal healing and alleviating inflammation simultaneously. These formulations were nontoxic and biocompatible with intestinal cells.
IBD, particularly ulcerative colitis, is KPV's most scientifically developed application area, with the most consistent and replicated preclinical data in the series. The PepT1 transporter mechanism is genuinely elegant: selective upregulation in inflamed colonic tissue creates inherent disease-site targeting with oral administration. The 2017 nanoparticle delivery innovation substantially strengthens the translational pathway. The mechanistic data from Gastroenterology (2008) is high-quality foundational science in one of gastroenterology's top-tier journals. The critical missing piece is a human Phase 1/2 trial. There is no commercial sponsor and no IND. The primary barrier to clinical development is commercial, not scientific.
Sung et al. (2025, Tissue and Cell): KPV inhibits ERK/p38 MAPK/NF-kB signaling and blocks caspase-1 activation in human HaCaT keratinocytes exposed to fine particulate matter (PM10) at 50 micrograms/mL, reducing both inflammation and cell death caused by environmental pollutant exposure. Validated in a three-dimensional skin model, strengthening translational relevance. KPV restored cell viability, reduced IL-1beta secretion, and prevented PM10-induced pyroptosis.
In experimental contact dermatitis models, epicutaneous application of alpha-MSH and KPV suppressed both the sensitization and elicitation phases of the cutaneous immune response. KPV retains the anti-inflammatory properties of the parent molecule in skin tissue while avoiding melanogenic effects.
The primary bottleneck for dermatological applications is delivery: KPV is highly hydrophilic with poor skin penetration limiting conventional topical formulations. Pawar et al. (2017) demonstrated that iontophoresis enhanced permeation, showing a 30-fold increase in flux across microporated human skin, a significant advance, though iontophoresis has not yet been validated in dermatological clinical trials.
The dermatology application is scientifically credible with consistent data across contact dermatitis, psoriasis, eczema, and now environmental skin protection models. The 2025 PM10 study (Sung et al., Tissue and Cell) is the most recent mechanistic advance, confirming dual NF-kB and MAPK pathway suppression in human keratinocytes in a validated 3D skin model. The primary bottleneck is delivery: KPV's hydrophilicity requires formulation engineering (iontophoresis, microneedles, specialized creams) for meaningful dermal penetration. No human dermatological trials exist.
Bonfiglio et al. (2006) demonstrated dose-dependent corneal epithelial wound healing acceleration via nitric oxide pathway modulation in rabbit corneal models. This is the most direct wound healing study for KPV specifically.
The 2025 International Journal of Medical Sciences tripeptide wound healing review confirmed that KPV-loaded hydrogels reduce inflammation, promote tissue regeneration, and combat MRSA infections in preclinical wound models. The dual anti-inflammatory and antimicrobial profile is uniquely suited to infected wound management where conventional anti-inflammatory drugs can worsen infection by suppressing immunity, while KPV's antimicrobial activity against S. aureus (including MRSA) and C. albicans at picomolar concentrations means it addresses both the infection and the inflammation simultaneously.
In wound healing models more broadly, KPV's mechanism through MC1R in fibroblasts, keratinocytes, and endothelial cells provides mechanistic plausibility: all three cell types are directly involved in wound repair, and activation via MC1R promotes their migration and function.
Wound healing is one of the most mechanistically plausible applications for KPV given MC1R expression in all three primary wound healing cell types. The MRSA-relevant hydrogel data is the most clinically compelling recent finding: infected wounds represent a major unmet need where KPV's dual mechanism (anti-inflammatory plus antimicrobial) is a genuine differentiator from compounds that address only one dimension. Corneal wound healing via nitric oxide adds an ophthalmic angle. No human wound healing trials exist.
Singh and Mukhopadhyay (2011) established that the C-terminal amino acids of alpha-MSH, specifically the KPV sequence, are the minimal region required for bacteriostatic activity against Staphylococcus aureus including methicillin-resistant strains (MRSA). The activity occurs via cAMP elevation within the bacterial cell, a mechanism distinct from conventional antibiotics, reducing the likelihood of cross-resistance.
Cutuli et al. (2000) confirmed that alpha-MSH peptides including KPV demonstrate antimicrobial effects at physiological picomolar concentrations, a concentration range achievable with oral or systemic administration. Crucially, these antimicrobial effects do not impair neutrophil killing of bacteria: they enhance it, making KPV mechanistically opposite to immunosuppressive agents that increase infection risk.
A dimeric form ([Ac-CKPV]2) showed enhanced candidacidal activity against Candida albicans beyond what the monomer achieves, suggesting opportunities for formulation optimization for fungal indications.
The antimicrobial data for KPV is genuinely distinct from what most anti-inflammatory peptides offer. Picomolar activity against MRSA via a cAMP-elevation mechanism with no impairment of neutrophil function is a pharmacological combination that conventional anti-inflammatory drugs cannot match. The clinical relevance is highest in infected wound scenarios and in IBD where bacterial dysbiosis contributes to disease. No human antimicrobial trials exist.
Viennois et al. (2016) demonstrated that KPV dramatically reduced colonic tumorigenesis in a murine model of colitis-associated colorectal cancer. Tumor numbers, sizes, and overall burden were all decreased in KPV-treated animals. This effect was abolished in PepT1-knockout mice, confirming absolute dependence on PepT1 uptake for the cancer-protective effect and directly connecting the IBD targeting mechanism to cancer prevention.
The mechanism is indirect: KPV does not act as a direct anti-tumor agent. It reduces the chronic colonic inflammation that drives colitis-associated cancer development. This is the inflammation-cancer continuum hypothesis, where reducing mucosal inflammation reduces the oncogenic stimulus that arises from chronic epithelial damage and cytokine-driven mutagenesis.
A single murine study with no replication and no human data. The mechanistic logic is scientifically sound: chronic IBD inflammation is a well-established driver of colitis-associated colorectal cancer, and reducing inflammation reduces cancer risk. The PepT1 dependence confirmation is scientifically elegant and links this finding directly to the established IBD targeting mechanism. This is hypothesis-generating only and should be characterized as such.
KPV has no human pharmacology data of any kind: no published human PK studies, no dose-finding studies, and no safety studies in humans. FDA regulatory status is in transition (Category 2 removal April 2026, PCAC review July 2026). Not WADA prohibited. Not currently on 503A positive list: compounding status transitional pending July 2026 PCAC determination. Research-grade quality standards: HPLC purity 98% or above, mass spectrometry confirmation of molecular weight (approximately 327 Da), sequence verification (Lys-Pro-Val, L-amino acids), endotoxin LAL test below 1 EU/mg for injectable use.
KPV vs BPC-157 (GI healing comparison): both are researched for IBD and GI healing, operating through mechanistically complementary pathways. BPC-157 works through VEGFR2-Akt-eNOS signaling to repair mucosal vasculature and promote angiogenesis. KPV works through PepT1-mediated NF-kB inhibition to suppress the inflammatory cascade. BPC-157 has Phase II IBD trial exposure (Croatia). KPV has the more precisely targeted oral delivery mechanism in IBD via PepT1 upregulation. These are more complementary than competitive.
KPV vs Thymosin Alpha-1 (anti-inflammatory comparison): both are anti-inflammatory but at completely different levels of biology. Tα1 modulates systemic immune responses through T-cell differentiation and TLR signaling, targeting the adaptive immune system broadly. KPV operates intracellularly in epithelial and mucosal cells via NF-kB inhibition, targeting the innate inflammatory machinery of specific tissue compartments. Tα1's evidence base is incomparably stronger: 35 or more country approvals vs KPV's zero human trials. They are non-competing and potentially synergistic.
KPV's preclinical safety data shows a favorable profile, but the absence of any completed human clinical trials means the safety picture is incomplete by definition.
Available data from preclinical studies suggests KPV does not suppress immune function broadly, does not increase infection risk (its antimicrobial properties theoretically reduce it), and does not cause tissue thinning associated with long-term corticosteroid use. Nanoparticle delivery formulations tested in colitis models were described as nontoxic and biocompatible with intestinal cells. No organ toxicity has been identified in preclinical protocols across multiple species.
There is a meaningful gap between the theoretical safety of a naturally derived tripeptide fragment of an endogenous hormone and formal clinical safety data. The absence of reported adverse events in the literature reflects the absence of human trial exposure, not confirmed safety in humans.
Theoretical cautions: melanocortin system modulation warrants caution in individuals with personal or family history of melanoma, given alpha-MSH's role in pigmentation signaling. No documented drug interactions. No pregnancy safety data: standard precautionary avoidance recommended.
No formal human contraindications have been established because no human trials have been completed.
KPV occupies the most preclinical-stage position among the free profiles in this series. It has no completed human clinical trials for any indication, placing it in a fundamentally different category from Thymosin Alpha-1 (11,000 or more subjects), TB4 (Phase 2 RCTs), and even BPC-157 (Phase II IBD exposure in Croatia).
What distinguishes KPV nonetheless is the quality and mechanistic clarity of its preclinical data, the elegance of its PepT1-mediated IBD targeting mechanism, its dual anti-inflammatory and antimicrobial properties (the opposite of immunosuppressive drugs that increase infection risk), and genuine innovation in delivery systems that specifically address its known pharmacological limitations.
The FDA regulatory position as of May 2026 is in transition. KPV was removed from Category 2 in April 2026 and the PCAC review in July 2026 will determine whether compounding pharmacies gain a clear pathway. The WADA position is clear: KPV is not prohibited, making it the most sport-friendly compound among the free profiles in this series for athletes in WADA-tested sports.
The path to human trials in IBD, which represents the clearest clinical rationale, is the most important next step. The primary barrier is commercial: as a naturally derived tripeptide fragment of an endogenous hormone, broad patent protection is difficult, reducing the commercial incentive needed to fund Phase 1/2 trials. Academic medical centers with IBD research programs remain the most realistic institutional home for KPV's first human trial.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use